Holding the Line in AML: Real-World Care Meets Breakthrough Trials
The HemOnc Pulse
00:00
Ziftomenib efficacy in relapsed AML
Wang reports a 33% response rate, 4.6-month median duration, and improved outcomes versus historic controls.
Play episode from 03:52
Transcript
